Payment overview · 2025
General Payments
$325.48
14 reported records · 4 companies
Healthcare provider profile · identity verified
Prashanth Mannam
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1104090935
Verified facts
What the public records show
CMS Open Payments records show Prashanth Mannam received $325.48 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 46.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.38 | 46.2% | 7 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $89.50 | 27.5% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $64.42 | 19.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.18 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.48 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.38 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $150.38 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $89.50 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $64.42 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 232 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 121 |
| Metformin Hcl | Metformin Hcl | 324 | 112 |
| Losartan Potassium | Losartan Potassium | 277 | 98 |
| Omeprazole | Omeprazole | 259 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 73 |
| Lisinopril | Lisinopril | 175 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 164 | 58 |
| Januvia | Sitagliptin Phosphate | 163 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 145 | 36 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 139 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 135 | 49 |
| Gabapentin | Gabapentin | 134 | 59 |
| Ozempic | Semaglutide | 123 | 33 |
| Montelukast Sodium | Montelukast Sodium | 121 | 42 |
| Simvastatin | Simvastatin | 108 | 38 |
| Ibuprofen | Ibuprofen | 107 | 36 |
| Meloxicam | Meloxicam | 104 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 32 |
| Jardiance | Empagliflozin | 91 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 36 |
| Furosemide | Furosemide | 87 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 36 |
| Nifedipine Er | Nifedipine | 85 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 28 |
| Meclizine Hcl | Meclizine Hcl | 79 | 26 |
| Carvedilol | Carvedilol | 72 | 23 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 22 |
| Enalapril Maleate | Enalapril Maleate | 64 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 36 |
| Eliquis | Apixaban | 59 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 21 |
| Prednisone | Prednisone | 56 | 32 |
| Famotidine | Famotidine | 53 | 16 |
| Azelastine Hcl | Azelastine Hcl | 52 | 19 |
| Azithromycin | Azithromycin | 50 | 43 |
| Farxiga | Dapagliflozin Propanediol | 47 | 16 |
| Trazodone Hcl | Trazodone Hcl | 46 | 16 |
| Trulicity | Dulaglutide | 46 | 11 |
| Lidocaine | Lidocaine | 45 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 23 |
| Sertraline Hcl | Sertraline Hcl | 42 | 13 |
| Donepezil Hcl | Donepezil Hcl | 38 | 15 |
| Linzess | Linaclotide | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Glipizide | Glipizide | 36 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Baclofen | Baclofen | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 30 | suppressed |
| Naproxen | Naproxen | 28 | 14 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.48 · 14 records | Novo Nordisk Inc | ACCRUFER, INSPIRE, MOUNJARO, Ozempic, Rybelsus, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error